Intravenous Lidocaine on Chronic Pain in Patients Undergoing Hepatectomy

Postoperative Chronic Pain Clinical Trial

Official title:

Effect of Prolonging Intravenous Lidocaine on Chronic Pain and Long-term Quality of Life in Patients Undergoing Hepatectomy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05492669
• Other study ID #: 2019-571
• Status: Recruiting
• Phase: Phase 2
• Start date: February 27, 2020
• Est. completion date: July 27, 2024

Study information

• Verified date: April 2024
• Source: West China Hospital
• Contact: Chunling Jiang, PhD
• Phone: 18980601096
• Email: jiang_chunling[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a further observation and follow-up of the patients enrolled in the registration number NCT04295330 to further evaluate the effect of long-term infusion of lidocaine on postoperative chronic pain, long-term quality of life and survival rate in patients undergoing liver cancer surgery.

Description:

This study is a further observation and follow-up of the patients enrolled in the registration number NCT04295330 to further evaluate the effect of long-term infusion of lidocaine on postoperative chronic pain, long-term quality of life and survival rate in patients undergoing liver cancer surgery. 272 patients with primary liver cancer who meet the inclusion criteria are included. According to the random number, the patients are divided into lidocaine group and conventional analgesia group.In the lidocaine group, a bolus injection of lidocaine 1.5 mg/kg, given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine , sufentanil , granisetron diluted to 200 mL in 0.9 % normal saline. In the placebo group, the same volume of normal saline instead of lidocaine will be administered. Blood samples will be drawn immediately after the bolus infusion of lidocaine, at the end of surgery, and 24 hours after surgery to measure plasma lidocaine concentrations. Blood samples will also be collected at 24 hours after surgery for subsequent measurement of inflammatory factors. Numeric rating scale(NRS) is used to evaluate pain at rest and light activities at postoperative 24, 48, 72 hours. The recovery time of postoperative gastrointestinal function, length of hospital stay, and the incidence of lidocaine toxicity within postoperative 72 hours will be recorded. Follow-up after discharge includes chronic pain, the impact of chronic pain on quality of life, the relapse-free survival and overall survival from postoperative 3 months to 5 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 260
• Est. completion date: July 27, 2024
• Est. primary completion date: July 27, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

Age: 18-80 years old American Society of Anesthesiologists(ASA) ?~III BMI=30 Primary single hepatocellular carcinoma resection was proposed for patients undergoing laparotomy (median incision, right subcostal incision/inverted L-shaped incision) Exclusion Criteria: Primary liver cancer with malignant tumors of other organs (such as lung, kidney, intestine, etc.). Primary hepatocellular carcinoma with portal vein or inferior vena cava and other large vascular thrombus. Long-term opioid use, alcohol or drug abuse or any of the drugs (lidocaine, etc.) used in this study were contraindicated and allergic for patients. Patients with severe hepatic and renal dysfunction (total bilirubin >1.46mg/dl, glomerular filtration rate <30ml/min /1.73? or end-stage renal disease). Severe heart disease (severe heart block (including sinoatrial, atrioventricular, and intraventricular block); Severe heart failure (ejection fraction <20%); Sinus bradycardia; Patients with Adams-Stokes syndrome, preexcitation syndrome, etc Patients with a history of uncontrolled seizures or acute porphyria. Long-term use of cimetidine and ß-blockers (lidocaine metabolism is inhibited through the liver, resulting in increased blood concentration of the drug, which can lead to adverse cardiac and nervous system reactions). Patients treated with drugs that are contraindicated with lidocaine (phenobarbital, thiopental, sodium nitroprusside, mannitol, amphotericin B, ampicillin, mesonotal, sulfadiazine sodium); Patients who are using enoxacin, lomefloxacin, norfloxacin, and prulifloxacin. Patients with a history of gastrointestinal bleeding or perforation after nsaids;Patients with active gastrointestinal ulcers/bleeding or who have had recurrent ulcers/bleeding in the past. Patients who had taken other experimental drugs or were participating or participating in other clinical trials within 3 months of enrollment. Failure to cooperate with the study for any reason or the researcher considers it inappropriate to be included in the study.

Related Conditions & MeSH terms

• Chronic Pain
• Postoperative Chronic Pain

Intervention

Drug:
• Lidocaine Hydrochloride, Injectable
In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 µg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
• 0.9% normal saline
In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 µg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.

Locations

Country	Name	City	State
China	West China Hospital	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
West China Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The prevalence of neuropathic pain	The ID Pain scale is used as a validated assessment of neuropathic pain. ID pain questionnaire consists of six items. Pain higher scores suggest a neuropathic component to the pain.	3 months, 6 months, 1 year, 3 years, 5 years postoperatively
Primary	The incidence of chronic pain at 3 months postoperatively	Chronic pain is defined as pain that lasts or recurs for longer than 3 months. For chronic postsurgical pain(CPSP), it mainly refers to the pain that persists past normal healing time. Pain scoring is performed at 3 months using the Numerical Rating Scale(NRS), with 11 digits ranging from 0 to 10 indicating the degree of pain,0 indicating no pain, and 10 indicating severe pain. Subjects choose a number to indicate the degree of pain based on their personal pain experience. The impact of chronic pain on the quality of life is also assessed by Brief Pain Inventory score.	3 months postoperatively
Secondary	The incidence of chronic pain at 6 months ,1 year,3 year and 5 year postoperatively	Chronic pain is defined as pain that lasts or recurs for longer than 3 months. For chronic postsurgical pain(CPSP), it mainly refers to the pain that persists past normal healing time. Pain scoring is performed at 3 months using the Numerical Rating Scale(NRS), with 11 digits ranging from 0 to 10 indicating the degree of pain,0 indicating no pain, and 10 indicating severe pain. Subjects choose a number to indicate the degree of pain based on their personal pain experience. The impact of chronic pain on the quality of life is also assessed by Brief Pain Inventory score.	6 months, 1 year and 3 year postoperatively
Secondary	The levels of inflammatory factors at 24 hours after surgery	Peripheral blood TNF-a, CXCL10, cytokines IL-6, three tumor progressions and metastasis-related markers (VEGF-A,MMP-3, MMP-9,MMP-2) etc. are measured 24 hours after operation.	24 hours postoperatively
Secondary	The incidence of moderate to severe pain at 24, 48 and 72 hours after surgery at rest and during movement;	The pain is evaluated using numerical rating scale(NRS). NRS scores range from 0 to 10 points, with 0 points representing no pain, 1-3 points representing mild pain, 4-6 points representing moderate pain, 7-9 points representing severe pain and 10 points.	At 3 days after surgery
Secondary	The cumulative morphine consumption at 24, 48 and 72 hours postoperatively	Intraoperative and postoperative opioid use is reported as morphine milligram equivalents, calculated using the Practical Pain Management calculator.	At the end of the surgery,24,48 and 72 hours after surgery
Secondary	The incidence of a composite of postoperative pulmonary complications during	defined as positive if any component developed before discharge after surgery; These complications included respiratory infection, respiratory failure, pleural effusion, atelectasis, pneumothorax, bronchospasm, or aspiration pneumonitis loading dose, immediately after the end of surgery, and at the first 24 hours after surgery.	during the period from the end of surgery to discharge
Secondary	Length of hospital stay	determined by the number of days from admittance to discharge.	during the period from the end of surgery to discharge
Secondary	Plasma lidocaine concentration immediately after loading,after surgery and 24-hours postoperatively	Plasma lidocaine concentration is an important indicator for evaluating the safety of the drug during use.	Immediately after bolus, after surgery and 24-hour postoperatively
Secondary	The incidence of lidocaine toxicity within 72 hours after operation	Lidocaine toxicity mainly includes neurological manifestations such as dizziness, tinnitus, convulsions, cardiac manifestations such as bradycardia, new severe atrioventricular block and so on.	within 72 hours after operation
Secondary	Overall survival after surgery	Overall survival is defined as the time between the date from surgery to the date of death.	6 months, 1 year, 3 years, 5 years postoperatively
Secondary	Recurrence-free survival after surgery	Postoperative re-examination is based on the diagnosis of enhanced CT, MRI, ultrasound or blood examination to determine whether the patient has recurrence and metastasis. Recurrence-free time refers to the time from surgery to tumor recurrence based on the above CT, MRI, etc.	6 months, 1 year, 3 years, 5 years postoperatively
Secondary	Disability-free surviva survival	Patient self-assessment is carried out by using the World Health Organization(WHO) Disability Scale, with a minimum score of 12 points and a maximum score of 60 points. The lower the score, the higher the quality of life.	6 months, 1 year, 3 years, 5 years postoperatively